Department of Medical Oncology, The First Medical Center, Chinese PLA General Hospital, Beijing, 100039 China.
ChosenMed Technology (Beijing) Co., Ltd, Beijing, 100176 China.
Immunotherapy. 2023 Feb;15(3):127-133. doi: 10.2217/imt-2022-0058. Epub 2023 Feb 1.
Most advanced colorectal cancer patients with proficient DNA mismatch repair or microsatellite stability (MSS) are insensitive to immune checkpoint inhibitor therapy. This report describes a heavily pretreated refractory colon adenocarcinoma patient with MSS. After experiencing four lines of treatment, the patient received the fifth-line therapy with the combined sintilimab, bevacizumab and chemotherapy. She achieved a long-term clinical outcome. The patient's progression-free survival after the fifth-line therapy was approximately 9.3 months, and her overall survival was approximately 57 months. To the best of our knowledge, this case represents the first report of durable clinical benefit from combination of an immune checkpoint inhibitor, bevacizumab and chemotherapy in a heavily pretreated patient with refractory metastatic colon adenocarcinoma with MSS.
大多数高水平 DNA 错配修复或微卫星稳定（MSS）的晚期结直肠癌患者对免疫检查点抑制剂治疗不敏感。本报告描述了一例 MSS 型难治性结肠腺癌的大量预处理患者。该患者经历了四线治疗后，接受了五线联合替西利珠单抗、贝伐珠单抗和化疗治疗。她获得了长期的临床获益。该患者接受五线治疗后的无进展生存期约为 9.3 个月，总生存期约为 57 个月。据我们所知，该病例是首例在 MSS 型难治性转移性结肠腺癌大量预处理患者中，联合免疫检查点抑制剂、贝伐珠单抗和化疗治疗获得持久临床获益的报道。
